| Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya® (NCT05230550) | Novo Nordisk A/S | 2022-02-03 |
| A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency (NCT05171855) | Ascendis Pharma Endocrinology Division A/S | 2021-12-16 |
| Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function. (NCT03212131) | Novo Nordisk A/S | 2017-08-16 |
| Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function (NCT03186495) | Novo Nordisk A/S | 2017-06-20 |
| A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of AGHD (NCT03104010) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2017-04-01 |
| Versartis International Trial in Adults With Long-Acting Growth Hormone (NCT02526420) | Versartis Inc. | 2015-07-01 |
| A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency (NCT02382939) | Novo Nordisk A/S | 2015-02-12 |
| Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD) (NCT02005198) | Novo Nordisk A/S | 2014-03-01 |
| An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD) (NCT01806298) | Merck KGaA, Darmstadt, Germany | 2013-06-01 |
| A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency (NCT01909479) | OPKO Health, Inc. | 2013-06-01 |
| A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency (NCT01706783) | Novo Nordisk A/S | 2012-10-12 |
| First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects (NCT01514500) | Novo Nordisk A/S | 2012-01-16 |
| Safety and Efficacy Study of Recombinant Human Growth Hormone in Adult Growth Hormone Deficiency Patients (NCT01822340) | Hanmi Pharmaceutical Company Limited | 2011-10-01 |
| The Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and Adrenocorticotropic Axis (NCT01282164) | The Cleveland Clinic | 2011-01-01 |
| A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth Hormone Deficiency (NCT01247675) | Ascendis Pharma A/S | 2010-11-01 |
| MOD-4023 (Long-Lasting Human Growth Hormone (hGH)) Study in Growth Hormone Deficient Adults (GHDA) (NCT01225666) | OPKO Health, Inc. | 2010-08-01 |
| Observational Study of the Safety and Efficacy of Norditropin® in Adult Patients With Growth Hormone Deficiency (NCT01109017) | Novo Nordisk A/S | 2009-10-01 |
| An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin® (NCT00934063) | Novo Nordisk A/S | 2009-07-01 |
| Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 (NCT00715689) | Novo Nordisk A/S | 2008-07-01 |
| Treatment of Adults With Growth Hormone Deficiency (NCT00596037) | LG Life Sciences | 2006-08-01 |
| Treatment of Adults With Growth Hormone Deficiency (NCT00294619) | LG Life Sciences | 2006-04-01 |
| Observational Prospective Study on Patients Treated With Norditropin® (NCT00960128) | Novo Nordisk A/S | 2006-04-01 |
| Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety (NCT00297713) | Altus Pharmaceuticals | 2005-07-01 |
| Long-term Trial on Growth Hormone Deficiency in Adults (GHDA) (NCT00184730) | Novo Nordisk A/S | 2004-11-01 |
| Long-term Trial on Growth Hormone Deficiency in Adults (GHDA) (NCT00184743) | Novo Nordisk A/S | 2003-12-06 |
| Metabolic Endocrinology and Growth Hormone in Adults (NCT01080755) | Merck KGaA, Darmstadt, Germany | 2003-12-01 |
| French National Registry of Adults With Growth Hormone Deficiency Treated With Somatropin (NCT01580605) | Novo Nordisk A/S | 2003-07-17 |
| Safety and Efficacy of Long-term Somatropin Treatment in Adults (NCT01543880) | Novo Nordisk A/S | 2003-07-01 |
| Growth Hormone Deficiency in Adults (GHDA) (NCT00519558) | Novo Nordisk A/S | 2003-05-31 |
| Extension Study on Safety of Long-Term Growth Hormone Replacement in Adult Patients With Growth Hormone Deficiency (NCT00191360) | Eli Lilly and Company | 2003-01-01 |
| Effect of Growth Hormone on Bone Mineral Density in Young Adults With Child-hood Onset Growth Hormone Deficiency (NCT00184678) | Novo Nordisk A/S | 2002-02-01 |
| Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency (NCT01698944) | Novo Nordisk A/S | 2001-05-16 |
| A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin (NCT00931476) | Novo Nordisk A/S | 2000-04-06 |
| Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients (NCT01562834) | Novo Nordisk A/S | 1998-10-21 |